Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Polymorphism in CYP2C9 as a Non-Critical Factor of Warfarin Dosage Adjustment in Korean Patients

  • Lee, Suk-Hyang (Graduate School of Clinical Pharmacy, Sookmyung Womens University) ;
  • Kim, Jae-Moon (Department of Neurology, Chungnam National University, School of Medicine) ;
  • Chung, Chin-Sang (College of Medicine, Department of Neurology, Samsung Medical Center, Sungkyunkwan University, School of Medicine) ;
  • Cho, Kyoung-Joo (College of Dentistry, Kyung Hee University) ;
  • Kim, Jeong-Hee (College of Dentistry, Kyung Hee University)
  • Published : 2003.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Cytochrome P4502C9(CYP2C9) is largely responsible for terminating anticoagulant effect by hydroxylation of S-warfarin to inactive metabolites. Mutations in the CYP2C9 gene result in the expression of allelic variants, CYP2C9*2 and CYP2C9*3 with reduced enzyme activity compared to wild type CYP2C9 *1. The aim of this study was to assess relationship between requirement of warfarin dose and polymorphism in CYP2C9 in Korean population. Patients on warfarin therapy for longer than 1 year were included from July 1999 to December 2000 and categorized as one of four groups; regular dose non-bleeding, regular dose bleeding, low dose non-bleeding and low dose bleeding. Low dose was defined as less than 10 mg/week for 3 consecutive monthly follow-ups. Bleeding complications included minor and major bleedings. Blood samples were processed for DNA extraction, genotyping and sequencing to detect polymorphism in CYP2C9. Demographic data, warfarin dose per week, prothrombin time (INR), indications and co-morbid diseases were assessed for each group. Total 90 patients on warfarin were evaluated; The low dose group has taken warfarin 7.6$\pm$1.7 mg/week, which was significantly lower than 31.4$\pm$0.9 mg/week in the regular dose group (p<0.0001). The measured INR in the low dose group was similar to that of the regular dose group (2.3$\pm$0.7 vs. 2.3$\pm$0.6, p=0.9). Even though there was a higher possibility of CYP2C9 variation in the low dose group, no polymorphism in CYP2C9 was detected. All patients were homozygous C416 in exon 3 for CYP2C9*2 and A1061 in exon 7 for CYP2C9*3. The DNA sequencing data confirmed the homozygous C416 and A 1061 alleles. In conclusion, polymorphism in CYP2C9 is not a critical factor for assessing warfarin dose requirement and risk of bleeding complications in a Korean population.

Keywords

References

  1. Aithal, G. P., Day, C. P., Kesteven, P. J. L., and Daly, A. K., Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353, 717-719 (1999) https://doi.org/10.1016/S0140-6736(98)04474-2
  2. Furuya, H, Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F., and Idle, J. R., Genetic polymorphism of CYP2C9 and its effects on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics, 5, 389-392 (1995) https://doi.org/10.1097/00008571-199512000-00008
  3. Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., and Ansell, J., et al., Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest,114, 445S-469S (1998) https://doi.org/10.1378/chest.114.5_Supplement.445S
  4. James, A. H., Britt, R. P., Risking, C. L., and Thompson, S. G., Factors affecting the maintenance dose of warfarin. J. Clin. Pathol., 45, 704-706 (1992) https://doi.org/10.1136/jcp.45.8.704
  5. Kaminsky, L. S. and Zhang, Z.-Y., Human p450 metabolism of warfarin. Pharmacol. Ther., 73, 67-74 (1997) https://doi.org/10.1016/S0163-7258(96)00140-4
  6. Kimura, M., Ieiri, I., Mamiya, K., Urae, A., and Higuchi, S., Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP in a Japanese population. Ther. Drug. Monit., 20, 243-247 (1998) https://doi.org/10.1097/00007691-199806000-00001
  7. Landefeld, C. S. and Beyth, R. J., Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med., 95, 315-328 (1993) https://doi.org/10.1016/0002-9343(93)90285-W
  8. Miners, J. O. and Birkett, D. J., Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 45, 277-280 (1998) https://doi.org/10.1046/j.1365-2125.1998.00674.x
  9. Nasu, K., Kubota, T., and Ishizaki, T., Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics, 7, 405-409 (1997) https://doi.org/10.1097/00008571-199710000-00011
  10. Redman, A. R., Implications of cytochrome P4502C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy, 21, 235-242 (2001) https://doi.org/10.1592/phco.21.2.235.34106
  11. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., and Korzekwa, K. R., Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39-42 (1994) https://doi.org/10.1097/00008571-199402000-00005
  12. Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., and Wolf, C. R., Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429-439 (1996) https://doi.org/10.1097/00008571-199610000-00007
  13. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., and Shenfield, G. M., et al., The role of the CYP2C9-Leu359 allelic variant in the tolbutamice polymorphism. Pharmacogentics, 6, 341-349 (1996) https://doi.org/10.1097/00008571-199608000-00007
  14. Takahashi, H., Kashima, T., Momizo, Y., Muramoto, N., Shimizu, T., and Nasu, K., et al., Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol. Ther., 63, 519-528 (1998) https://doi.org/10.1016/S0009-9236(98)90103-5
  15. Wang, S. L., Huang, J.-D., Lai, M. D., and Tsai, J. J., Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5, 37-42 (1995) https://doi.org/10.1097/00008571-199502000-00004
  16. Yoon, Y. R., Shon, J. H., Kim, M. K., Lim, Y. C., Lee, H. R., Park, J. Y., Cha, I. J., and Shin, J. G., Frequency of cytochorome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol., 51, 277-280 (2001) https://doi.org/10.1046/j.1365-2125.2001.00340.x